甲状腺乳头状癌颈侧区淋巴结转移与血清促甲状腺激素的相关关系研究
|
摘要
目的:探讨血清促甲状腺激素(TSH)与甲状腺乳头状癌(PTC)颈侧区淋巴结转移的相关关系,以期为临床诊疗提供理论依据。方法:纳入2013年9月至2018年8月我院甲乳外科收治的经病理确定为PTC的患者,其中存在颈侧区淋巴结转移患者共80例(观察组),无转移的患者共62例(对照组)。比较两组患者的一般临床资料,比较两组患者血清促甲状腺激素(TSH)水平,比较观察组不同病理资料TSH的水平。结果:共纳入观察组患者80例,对照组62例,两组一般临床资料比较无显著性差异(P>0.05)。观察组患者血清TSH(2.3±0.6uIU/mLVS1.1±0.4uIU/mL;t=13.58,P<0.01)水平显著高于对照组(P<0.05)。观察组患者不同病理资料之间血清TSH水平在性别、年龄方面相比无显著性差异(P>0.05),在钙化、TNM分期、肿瘤直径、是否颈侧区淋巴结转移方面相比具有显著性差异(P<0.05)。结论:血清TSH与PTC颈侧区淋巴结转移具有一定的相关关系,对于辅助PTC的诊疗具有一定的临床应用价值。
Objective:To explore the relationship between serum thyroid stimulating hormone(TSH) and cervical lymph node metastasis of thyroid papillary carcinoma(PTC), in order to provide a theoretical basis for clinical diagnosis and treatment. Methods:The clinical data(observation group) of 80 patients with pathologically confirmed PTC admitted to our hospital from September 2013 to August 2018,In the same period, the clinical data(control group) of 62 patients who were diagnosed as benign thyroid nodules after treatment in our hospital were included.The general clinical data of the two groups were compared. Serum thyroid stimulating hormone(TSH) levels were compared between the two groups. The levels of TSH in different pathological data were compared. Results: A total of 80 patients in the observation group and 62 patients in the control group were included. There was no significant difference in the general clinical data between the two groups(P>0.05). Serum TSH(2.3±0.6 uIU/ml VS 1.1±0.4 uIU/ml; t=13.58, P<0.01) was significantly higher in the observation group than in the control group(P<0.05). There was no significant difference in serum TSH levels between the different pathological data in the observation group(P>0.05). There were significant differences in calcification, TNM stage, tumor diameter, and cervical lymph node metastasis.(P<0.05). Conclusion:Serum TSH has a certain correlation with PTC cervical lymph node metastasis, and it has certain clinical application value for the diagnosis and treatment of assisted PTC.
Objective:To explore the relationship between serum thyroid stimulating hormone(TSH) and cervical lymph node metastasis of thyroid papillary carcinoma(PTC), in order to provide a theoretical basis for clinical diagnosis and treatment. Methods:The clinical data(observation group) of 80 patients with pathologically confirmed PTC admitted to our hospital from September 2013 to August 2018,In the same period, the clinical data(control group) of 62 patients who were diagnosed as benign thyroid nodules after treatment in our hospital were included.The general clinical data of the two groups were compared. Serum thyroid stimulating hormone(TSH) levels were compared between the two groups. The levels of TSH in different pathological data were compared. Results: A total of 80 patients in the observation group and 62 patients in the control group were included. There was no significant difference in the general clinical data between the two groups(P>0.05). Serum TSH(2.3±0.6 uIU/ml VS 1.1±0.4 uIU/ml; t=13.58, P<0.01) was significantly higher in the observation group than in the control group(P<0.05). There was no significant difference in serum TSH levels between the different pathological data in the observation group(P>0.05). There were significant differences in calcification, TNM stage, tumor diameter, and cervical lymph node metastasis.(P<0.05). Conclusion:Serum TSH has a certain correlation with PTC cervical lymph node metastasis, and it has certain clinical application value for the diagnosis and treatment of assisted PTC.
引文
[1] Jo K,Lim DJ.Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer[J].Korean Intern Med,2018,33(6):1050～1057.
[2] Veedu JS,Mathew A.Are we missing the elephant in the room a case for thyroid cancer overdiagnosis as the etiology for its increasing incidence in india[J].Glob Oncol,2018,(4):1～3.
[3] Abraham E,Tran B,Roshan D,et al.Response to Re:Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence[J].ANZ Surg,2018,88(11):1212～1213.
[4] Xia F,Chen Y,Jiang B,et al.Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway[J].Cell Physiol Biochem,2018,50(5):1659～1672.
[5] Lin YH,Wu MH,Huang YH,et al.Thyroid hormone negatively regulates tumorigenesis through suppression of BC200[J].Endocr Relat Cancer,2018,25(12):967～979.
[6] Hwangbo Y,Lee EK,Son HY,et al.Genome-wide association study reveals distinct genetic susceptibility of thyroid nodules from thyroid cancer[J].Clin Endocrinol Metab,2018,103(12):4384～4394.
[7] Damiani L,Lupo S,Rossi R,et al.Evaluation of the role of BRAFV600E somatic mutation on papillary thyroid cancer disease persistence:a prospective study[J].Eur Thyroid,2018,7(5):251～257.
[8] Zheng G,Zhang H,Hao S,et al.Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis[J].Oncotarget,2017,8(34):57089～57098.
[9] Guo F,Hou X,Sun Q.MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF[J].Oncol Lett,2018,16(5):6815～6821.
[2] Veedu JS,Mathew A.Are we missing the elephant in the room a case for thyroid cancer overdiagnosis as the etiology for its increasing incidence in india[J].Glob Oncol,2018,(4):1～3.
[3] Abraham E,Tran B,Roshan D,et al.Response to Re:Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence[J].ANZ Surg,2018,88(11):1212～1213.
[4] Xia F,Chen Y,Jiang B,et al.Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway[J].Cell Physiol Biochem,2018,50(5):1659～1672.
[5] Lin YH,Wu MH,Huang YH,et al.Thyroid hormone negatively regulates tumorigenesis through suppression of BC200[J].Endocr Relat Cancer,2018,25(12):967～979.
[6] Hwangbo Y,Lee EK,Son HY,et al.Genome-wide association study reveals distinct genetic susceptibility of thyroid nodules from thyroid cancer[J].Clin Endocrinol Metab,2018,103(12):4384～4394.
[7] Damiani L,Lupo S,Rossi R,et al.Evaluation of the role of BRAFV600E somatic mutation on papillary thyroid cancer disease persistence:a prospective study[J].Eur Thyroid,2018,7(5):251～257.
[8] Zheng G,Zhang H,Hao S,et al.Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis[J].Oncotarget,2017,8(34):57089～57098.
[9] Guo F,Hou X,Sun Q.MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF[J].Oncol Lett,2018,16(5):6815～6821.